5th HIV Research for Prevention Conference (HIVR4P 2024)

Sessions & Speakers

1. Sunday 10/06

   Satellite | 14:30–16:00 PET (GMT-5 hours) | Limatambo 2/Channel 2

   Delivering on the promise: Defining optimal implementation strategies and service delivery packages for the Dual Prevention Pill
   

   AVAC, Population Council, UNICEF

    

   The Dual Prevention Pill (DPP), which co-formulates oral pre-exposure prophylaxis (PrEP) and combined oral contraception in a single pill, could receive regulatory approval by 2025 and become the first multi-purpose prevention technology (MPT) with PrEP available. Planning for DPP implementation requires integrating best practices from PrEP and contraceptive provision to deliver an MPT, as integrating PrEP and family planning (FP) services has historically been a challenge.

    

   This session will look at lessons from PrEP and FP implementation and scale-up to explore optimal implementation strategies for the DPP. Presenters will discuss potential scenarios for integrating the DPP in HIV prevention and FP provision, including approaches to reach and support different user segments, particularly young women; what healthcare providers will need to do differently to deliver an MPT; and the key questions, populations, and settings that implementation science studies on the DPP could focus on. Discussion will chart a way forward for DPP delivery.

    

   Recording and slide deck are available here (Council’s Sanyukta Mathur’s presentation is from 27:40 to 36:31)

2. Monday 10/07

   Press Conference | 10:00–11:00 PET (GMT-5 hours) | Press Conference Room

   HIVR4P Scientific Highlights press conference

    

   “Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg)”

   Jeremy Nuttall

   (Oral presentation took place on 9 October)

   E-poster | NA | Online

   “’DPP is good because you will be taking it as one pill’ Attitudes and experiences with the dual prevention pill (DPP) among adolescent girls and young women in Harare, Zimbabwe” (Abstract)

   A. Dandadzi*, I. Bruce, N. Sedze, M. Frix, P. Musara, P. Mutero, C. Murombedzi, B.A. Friedland, N. Mgodi, and S. Mathur

    

   Poster can be viewed here

    

   “End user market segmentation, messaging and positioning for the dapivirine vaginal ring: A Lesotho case study” (Abstract)
   

   D. Pillay*, F. Mahiaini, D. Phenethi, S. Pato, S. Tenn, M. Motlatsi, and L. Solai

    

   Poster can be viewed here

    

   “High levels of vulnerability among adolescent girls and young women (AGYW) enrolled in a crossover pilot study of a dual prevention pill for HIV and pregnancy prevention in Harare, Zimbabwe” (Abstract)

   M. Nkangu*, M. Plagianos, A. Dandadzi, V. Gatsi, S. Matimbira, C. Murombedzi, P. Musara, I.V. Bruce, J.B. Burnett-Zieman, N.M. Mgodi, S. Mathur, and B.A. Friedland

    

   Poster can be viewed here

3. Tuesday 10/08

   Symposium | 13:30–15:00 PET (GMT-5 hours) | Limatambo 5/Channel 3

   Session: Other prevention modalities and cross-cutting issues

    

   “Multipurpose technology in STI control”

   Lisa Haddad*
   

    

   Recording and slide deck are available here (Presentation is from 55:35 to 1:14:26)

   Poster Late Breaker | 17:00–19:00 PET (GMT-5 hours) | Poster Exhibition (Levels 3&4)

   “Correlates of adherence to oral PrEP or a dual prevention pill in a crossover clinical trial in Harare, Zimbabwe and Johannesburg, South Africa” (Abstract)

   Marlena Plagianos*, D. Bryant, C. Murombedzi, B. Zieman, S. Mathur, I. Bruce, A. Dandadzi, P. Musara, S. Zulu, K. Reddy, N. Cassim, L. Haddad, T. Palanee-Phillips, N. Ndlovu, N. Mgodi, B. Friedland

4. Wednesday 10/09

   Oral Late Breaker | 10:30–12:00 PET (GMT-5 hours) | Limatambo 3/Channel 1

   “Pharmacokinetic superiority of a 3-month dapivirine vaginal ring (100 mg) compared to the 1-month dapivirine vaginal ring (25 mg)” (Abstract)
   

   J. Nuttall,* L. Haddad, M. Plagianos, W. Kriel, J. Visser, L. Solai, A. Garg, J. Steytler, and B. Devlin

    

   Oral | 17:30–19:00 PET (GMT-5 hours) | Limatambo 3/Channel 1

   “Are women interested in a nonhormonal multipurpose prevention technology (MPT) vaginal ring? Results from a national online survey with U.S. women” (Abstract)

   Ann Gottert, S. Mathur*, T. Abuya, I. Bruce, S. Shetty, M. Nguyen, J.M. Sales, L.B. Haddad, and B.A. Friedland

   Poster Exhibition | 19:00–20:30 PET (GMT-5 hours) | Poster Exhibition (Levels 3&4)

   “Acceptability of the 3-month dapivirine ring versus the 1-month dapivirine vaginal ring: Qualitative findings from a crossover bioavailability trial among 18- to 45-year-old women in Bloemfontein, South Africa” (Abstract)

   B. Friedland, M Nunu, S Clarke-Von Witt, E Dorman, J Visser, W Kriel, J Steytler, and B Devlin

    

   “Comparison of self-reported, pill count and biomarker measures of adherence to oral PrEP or a dual prevention pill in crossover clinical trial in Harare, Zimbabwe” (Abstract)

   Marlena Plagianos*, N.M. Mgodi, B. Zieman, S. Mathur, I. Bruce, A. Dandadzi, P. Musara, C. Murombedzi, L. Haddad, and B. Friedland

    

   “Development of a multipurpose intravaginal ring for controlled release of Q-Griffithsin combined with contraceptive hormones: In vitro and in vivo evaluation” (Abstract)

   M.M. Baum, M. Gunawardana, J. Breslin, I. Butkyavichene, A.E. Castonguay, D.B. Diener, S. Gunawardana, M. Remedios-Chan, J.A. Moss, P. Barnable, T. Bonnaire, J. Fernandez-Romero, M. Aravantinou, F. Schiro, B. Grasperge, N. Derby, P. Angsantikul, N. Kumar, B. Variano, and Natalia Teleshova*

    

   “Experiences with and recommendations for a dual prevention pill (DPP) for HIV and pregnancy prevention: in-depth interviews with women participating in a crossover acceptability study in Johannesburg, South Africa

   S. Tenza^*, M. Moji, P. Sibiya, P. Makau, S.K. Zulu, I. Bruce, K. Reddy, B. Friedland, T. Palanee-Phillips, and S. Mathur

    

   “Preference for and adherence to a dual prevention pill (DPP) versus two separate pills for PrEP and contraception among women in Johannesburg, South Africa” (Abstract)

   B. Zieman, Marlena Plagianos*, T. Palanee, S. Reddy, N. Ndlovu, S. Zulu, I. Bruce, S. Mathur, L. Shale, L.B. Haddad, and B. Friedland

    

   “Safety/pharmacokinetics/pharmacodynamics and immunogenicity studies of Griffithsin fast dissolving insert in rhesus macaques” (Abstract)

   P. Barnable, M.L. Visciano, M. Aravantinou, N. Kommineni, J. Gadsden, F. Schiro, L. Guzmán, B. Grasperge, P. Angsantikul, J. Fernandez-Romero, L.B. Haddad, and Natalia Teleshova*